Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex (VRTX) PT Raised to $459 at Morgan Stanley
February 11, 2025 7:10 AM ESTMorgan Stanley analyst Terence Flynn raised the price target on Vertex (NASDAQ: VRTX) to $459.00 (from $450.00) while maintaining a Equalweight rating.
The analyst comments "VRTX posted a 4Q beat and first time 2025 Rev/expense guidance bracketed consensus. Looking ahead the focus is on... More
